Phase 3 Microsatellite Instability Clinical Trials

3 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 1–3 of 3 trials

Recruiting

Phase 3

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Triple-Negative Breast CancerCervical CancerUrothelial Carcinoma+12 more

UNICANCER646 enrolled40 locationsNCT05078047

Recruiting

Phase 3

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)

Centre Hospitalier Universitaire Dijon68 enrolled1 locationNCT06762405

Recruiting

Phase 3

Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer

Colorectal, CancerMicrosatellite Instability High

Sun Yat-sen University180 enrolled1 locationNCT06520683